Journal List > J Korean Soc Magn Reson Med > v.16(1) > 1011860

TOOLS
Kim, Oh, Park, Kang, Ahn, and Chung: Evaluation of Optimal Combination of Commercially Available Superparamagnetic Iron Oxide Nanoparticles and Transfection Agents for Labelling of Human Mesenchymal Stem Cells
Original Article
Journal of the Korean Society of Magnetic Resonance in Medicine

Journal of the Korean Society of Magnetic Resonance in Medicine 2012; 16(1): 31-39.

Published online: 30 April 2012

DOI: https://doi.org/10.0000/jksmrm.2012.16.1.31

Evaluation of Optimal Combination of Commercially Available Superparamagnetic Iron Oxide Nanoparticles and Transfection Agents for Labelling of Human Mesenchymal Stem Cells

Sung Hun Kim1, Soon Nam Oh1, Youn Hee Park1, Won Kyung Kang2, Kook Jin Ahn1, Soo Kyo Chung1

1Department of Radiology, College of Medicine, The Catholic University of Korea, Korea.

2Department of General Suregery, College of Medicine, The Catholic University of Korea, Korea.

Corresponding author: Kook Jin Ahn, M.D., Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 505 Banpo-dong, Seocho-gu, Seoul 137-701, Korea. Tel. 82-2-2258-1455, Fax. 82-2-2258-1457, ahn-kj@catholic.ac.kr

Received 15 November 2011       Revised 23 December 2011       Accepted 23 December 2011

Copyright © 2012 Korean Society of Magnetic Resonance in Medicine

Abstract

Purpose

To determine the optimal combination of commercially available superparamagnetic iron oxide (SPIO) nanoparticles with transfection agents (TA).

Materials and Methods

Protamine sulfate (Pro) and poly-L-lysin (PLL) were incubated with ferumoxide and ferucarbotran in human mesenchymal stem cells at various concentrations, and cellular viability were evaluated. Cellular iron uptake was qualitatively and quantitatively evaluated. Cell visibility was assessed via MR imaging and the T2-relaxation time was calculated.

Results

The cellular viabilities with ferucarbotran were more significantly decreased than those with ferumoxide (p < 0.05). Iron uptake with ferumoxide was significantly higher than that for those with with ferucarbotran. The T2-relaxation time was observed to be shorter with ferumoxide in comparison to those with ferucarbotran (p < 0.05). Ferumoxide at a concentration of 25 µg/ml in combination with either Pro or PLL at a concentration of 3.0 µg/ml did not adversely impact cell viability, maximized iron uptake, and exhibited a lower T2-relaxation time in comparison to other combinations.

Conclusion

Stem cells with ferumoxide exhibited a higher cellular viability and iron uptake in comparison to ferucarbotran- treated stem cells. A 25 µg/ml of ferumoxide with a 3.0 µg/ml of TA is sufficient to label mesenchymal stem cells.

Keywords: Cell labeling, Contrast media, Experimental studies, Iron, Magnetic resonance (MR)

References

1. Arbab AS, Yocum GT, Kalish H, et al. Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. Blood. 2004. 104:1217–1223.
2. Janic B, Rad AM, Jordan EK, et al. Optimization and validation of fepro cell labeling method. PLoS One. 2009. 4:e5873.
3. Mailander V, Lorenz MR, Holzapfel V, et al. Carboxylated superparamagnetic iron oxide particles label cells intracellularly without transfection agents. Mol Imaging Biol. 2008. 10:138–146.
4. van Buul GM, Farrell E, Kops N, et al. Ferumoxides-protamine sulfate is more effective than ferucarbotran for cell labeling: implications for clinically applicable cell tracking using MRI. Contrast Media & Molecular Imaging. 2009. 4:230–236.
5. Daldrup-Link HE, Rudelius M, Piontek G, et al. Migration of iron oxide-labeled human hematopoietic progenitor cells in a mouse model: in vivo monitoring with 1.5-t MR imaging equipment. Radiology. 2005. 234:197–205.
6. Arbab AS, Yocum GT, Wilson LB, et al. Comparison of transfection agents in forming complexes with ferumoxides, cell labeling efficiency, and cellular viability. Mol Imaging. 2004. 3:24–32.
7. Bulte JW, Douglas T, Witwer B, et al. Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat Biotechnol. 2001. 19:1141–1147.
8. Josephson L, Tung CH, Moore A, Weissleder R. High-efficiency intracellular magnetic labeling with novel superparamagnetic-tat peptide conjugates. Bioconjug Chem. 1999. 10:186–191.
9. Kircher MF, Allport JR, Graves EE, et al. In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic t-lymphocyte trafficking to tumors. Cancer Res. 2003. 63:6838–6846.
10. Arbab AS, Bashaw LA, Miller BR, Jordan EK, Bulte JW, Frank JA. Intracytoplasmic tagging of cells with ferumoxides and transfection agent for cellular magnetic resonance imaging after cell transplantation: methods and techniques. Transplantation. 2003. 76:1123–1130.
11. Frank JA, Miller BR, Arbab AS, et al. Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents. Radiology. 2003. 228:480–487.
12. Daldrup-Link HE, Rudelius M, Oostendorp RA, et al. Targeting of hematopoietic progenitor cells with MR contrast agents. Radiology. 2003. 228:760–767.
13. Kraitchman DL, Heldman AW, Atalar E, et al. In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. Circulation. 2003. 107:2290–2293.
14. Bowen CV, Zhang X, Saab G, Gareau PJ, Rutt BK. Application of the static dephasing regime theory to superparamagnetic iron-oxide loaded cells. Magn Reson Med. 2002. 48:52–61.
15. Frank JA, Zywicke H, Jordan EK, et al. Magnetic intracellular labeling of mammalian cells by combining (fda-approved) superparamagnetic iron oxide MR contrast agents and commonly used transfection agents. Acad Radiol. 2002. 9:Suppl 2. S484–S487.
16. Ju S, Teng G, Zhang Y, Ma M, Chen F, Ni Y. In vitro labeling and MRI of mesenchymal stem cells from human umbilical cord blood. Magn Reson Imaging. 2006. 24:611–617.
17. Arbab AS, Bashaw LA, Miller BR, et al. Characterization of biophysical and metabolic properties of cells labeled with superparamagnetic iron oxide nanoparticles and transfection agent for cellular MR imaging. Radiology. 2003. 229:838–846.
18. Arbab AS, Yocum GT, Rad AM, et al. Labeling of cells with ferumoxides-protamine sulfate complexes does not inhibit function or differentiation capacity of hematopoietic or mesenchymal stem cells. NMR Biomed. 2005. 18:553–559.
19. Sorgi FL, Bhattacharya S, Huang L. Protamine sulfate enhances lipid-mediated gene transfer. Gene Ther. 1997. 4:961–968.
20. Bulte JW, Kraitchman DL, Mackay AM, Pittenger MF. Chondrogenic differentiation of mesenchymal stem cells is inhibited after magnetic labeling with ferumoxides. Blood. 2004. 104:3410–3412. author reply 3412-3413.
21. Bashford CL, Alder GM, Menestrina G, Micklem KJ, Murphy JJ, Pasternak CA. Membrane damage by hemolytic viruses, toxins, complement, and other cytotoxic agents. A common mechanism blocked by divalent cations. J Biol Chem. 1986. 261:9300–9308.
22. Strand BL, Ryan TL, In't Veld P, et al. Poly-l-lysine induces fibrosis on alginate microcapsules via the induction of cytokines. Cell Transplant. 2001. 10:263–275.
23. Song M, Moon WK, Kim Y, Lim D, Song IC, Yoon BW. Labeling efficacy of superparamagnetic iron oxide nanoparticles to human neural stem cells: comparison of ferumoxides, monocrystalline iron oxide, cross-linked iron oxide (clio)-nh2 and tat-clio. Korean J Radiol. 2007. 8:365–371.
24. Oude Engberink RD, van der Pol SM, Dopp EA, de Vries HE, Blezer EL. Comparison of spio and uspio for in vitro labeling of human monocytes: MR detection and cell function. Radiology. 2007. 243:467–474.
TOOLS
Similar articles